There's a real biological basis: estrogen receptors are present throughout the inner ear, and in a very large UK Biobank study of over 214,000 women, both natural and surgical menopause were independently associated with a substantially higher risk of hearing loss compared with premenopause.

A smaller longitudinal study found high-frequency hearing decline accelerated specifically in the years right after the final menstrual period. What's genuinely not settled, and often gets left out of the popular framing, is whether hormone therapy helps or hurts: the Nurses' Health Study II found oral hormone therapy was associated with a duration-dependent INCREASE in hearing loss risk, and the same UK Biobank analysis that found menopause itself raises risk also found hormone therapy use was associated with increased risk in typical-age menopause. Given that hearing loss is one of the largest modifiable dementia risk factors identified in major research, a baseline hearing check around midlife is a reasonable thing to ask for, regardless of how the hormone therapy question resolves.

What to know about this answer

Whether hormone therapy protects or harms hearing is a genuinely open and contested question, unlike the more settled finding that menopause itself is associated with faster hearing decline.

What the research shows, and which source each finding rests on

Estrogen receptors alpha and beta are present in the inner ear of mice, rats and humans; estrogen receptor beta knockout mice develop severe progressive hearing loss; women with Turner syndrome, who are estrogen-deficient, show early presbycusis.

E[1]

In 214,327 UK Biobank women, both natural (HR 2.49) and surgical menopause (HR 2.71) were associated with higher hearing-loss risk versus premenopause, and premature menopause (before 40) carried HR 1.27 versus typical-age menopause.

C[2]

In 104 healthy women followed about 7.5 years with audiometry, the years right after the final menstrual period showed high-frequency hearing decline of roughly 0.9-1.5 dB per year.

D[3]

Hearing loss is one of the largest modifiable dementia risk factors identified in the 2020 Lancet Commission model.

A[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Estrogen-protective

The Karolinska group (Hederstierna, Hultcrantz); most menopause educators including Mary Claire Haver, MD

Menopause triggers hearing decline through loss of estrogen's support in the inner ear, and audiometric cohort data show hormone therapy users hearing better than non-users at certain frequencies.

E[1]D[3]

Hormone therapy neutral-to-harmful

Curhan et al., Nurses' Health Study II; the UK Biobank analysis

In a study of 80,972 women, oral hormone therapy showed a duration-dependent INCREASE in hearing-loss risk (RR 1.21 for 10+ years of use); the 2025 UK Biobank analysis found menopause itself raised risk, yet hormone therapy use was also associated with increased hearing-loss risk in typical-age menopause.

C[2]C[5]

What would settle it: A randomized trial with audiometric endpoints, or at minimum prospective audiometry across the transition with treatment stratified by formulation, route and timing, would settle this; no such study currently exists, so a confident claim that hormone therapy protects hearing outruns the evidence, as does the claim that menopause has nothing to do with hearing.

What is really going on here

  1. Midlife hearing: can I get a baseline audiogram?

Questions for your doctor

  1. Can I get a baseline audiogram now, given the hearing-dementia risk connection?
  2. If I'm on or considering hormone therapy, what does the evidence say about its effect on hearing specifically?
  3. Does my family or personal hearing history change how we should approach this?
  4. What would prompt a referral to an audiologist or ENT?

Questions with no answer yet

Would a randomized trial with audiometric endpoints find that hormone therapy protects hearing, harms it, or has no effect, resolving the current contradiction between studies pointing in different directions?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Nobody has run a randomized trial with audiometric endpoints. Some cohort data show hormone therapy users hearing better at certain frequencies, while a large study of oral hormone therapy found a duration-dependent increase in hearing-loss risk, and the most recent very large study found both that menopause raises risk and that hormone therapy use is also associated with increased risk in typical-age menopause.

What would test it: A randomized trial with audiometric endpoints, or at minimum prospective audiometry across the transition with treatment stratified by formulation, route, and timing.

Does the route of hormone delivery matter for hearing the way it may for other outcomes in this knowledge base, meaning could a transdermal formulation have a different effect on hearing than the oral formulations used in the studies showing harm?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The study finding a duration-dependent increase in hearing-loss risk specifically measured oral hormone therapy, without a study isolating transdermal formulations specifically for hearing outcomes, even though route-specific differences are documented for other outcomes elsewhere in this knowledge base.

What would test it: A study specifically comparing hearing outcomes between oral and transdermal hormone therapy users.

Since hearing loss is described as one of the largest modifiable dementia risk factors, would treating hearing loss itself, independent of its cause, in midlife women measurably reduce their later dementia risk, the way it is hypothesized to for the general population?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The dementia-risk-factor finding comes from a general population model, not a study specifically testing hearing intervention in midlife women transitioning through menopause, and there is no dedicated trial connecting menopause-related hearing decline treatment to downstream dementia outcomes.

What would test it: A trial or long-term cohort study testing whether treating midlife hearing loss, regardless of cause, in women around the menopause transition reduces later dementia incidence.

Sources

  1. 1.Estrogen and hearing: a summary of recent investigations.Hultcrantz M, Simonoska R, Stenberg AE. Estrogen and hearing: a summary of recent investigations. Acta Otolaryngol 2006;126(1):10-4 · Review, opinion or mechanism
  2. 2.Reproductive milestones, use of menopausal hormone therapy, and risk of hearing loss: A life course study of 214 327 women.Fu C, et al. Reproductive milestones, use of menopausal hormone therapy, and risk of hearing loss: a life course study of 214,327 women. Maturitas 2025;201:108685 · Observational study
  3. 3.The menopause triggers hearing decline in healthy women.Hederstierna C, et al. The menopause triggers hearing decline in healthy women. Hear Res 2010;259(1-2):31-5 · Comparative or small study
  4. 4.Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.Livingston G, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396(10248):413-446 · Systematic review or guideline
  5. 5.Menopause and postmenopausal hormone therapy and risk of hearing loss.Curhan SG, et al. Menopause and postmenopausal hormone therapy and risk of hearing loss. Menopause 2017;24(9):1049-1056 · Observational study

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides